Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy

Area of Science:

• Cardiology
• Hepatology
• Molecular Biology

Background:

• Cirrhotic cardiomyopathy is a common comorbidity in end-stage liver disease, affecting approximately 50% of patients awaiting liver transplantation.
• This condition involves structural, functional, hemodynamic, and electrocardiographic abnormalities of the heart, directly linked to liver damage.
• It is associated with increased mortality, morbidity, and multi-organ failure, particularly in patients undergoing liver transplantation or porto-systemic shunt procedures.

Purpose of the Study:

• To review and elucidate the molecular mechanisms underlying the liver-heart interaction in cirrhotic cardiomyopathy.
• To highlight the current lack of specific treatments due to incomplete understanding of the disease's pathogenesis.
• To provide insights that can guide the development of targeted therapies for cirrhotic cardiomyopathy.

Main Methods:

• This is a review article, synthesizing existing scientific literature on cirrhotic cardiomyopathy.
• Focus is placed on molecular mechanisms driving the interaction between the cirrhotic liver and the heart.
• Literature search and analysis of studies investigating the etio-pathogenesis of liver-heart interactions.

Main Results:

• Cirrhotic cardiomyopathy presents with significant cardiac dysfunction in patients with advanced liver disease.
• The precise molecular pathways linking liver pathology to cardiac dysfunction remain incompletely understood.
• Despite clinical significance, no specific treatments are currently available for this condition.

Conclusions:

• A deeper understanding of the molecular mechanisms is crucial for developing targeted treatments for cirrhotic cardiomyopathy.
• Effective therapies could prevent or reverse cardiac complications of liver failure, improving patient outcomes.
• Further research into the liver-heart axis is essential for advancing care for patients with cirrhosis.